# Neuronetics, Inc.: financial statements, quarterly

STIM · Nasdaq · CIK 1227636 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/stim.md) · [Financials](/companies/stim/financials.md) · [Filings](/companies/stim/filings.md) · [Insiders](/companies/stim/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/stim/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [17.9](/filings/0001558370-24-015160.md) | [20.3 d](/filings/0001104659-26-029004.md) | [17.4](/filings/0001558370-25-006384.md) | [16.5](/filings/0001558370-25-010180.md) | [18.5](/filings/0001104659-25-105924.md) | [22.5 d](/filings/0001104659-26-029004.md) | [32.0](/filings/0001104659-26-055322.md) | [38.1](/filings/0001104659-26-094078.md) | [37.3](/filings/0001104659-25-105924.md) | [41.8 d](/filings/0001104659-26-029004.md) | [34.5](/filings/0001104659-26-055322.md) | [41.6](/filings/0001104659-26-094078.md) |
| Cost of revenue | $m | [6.1](/filings/0001558370-24-015160.md) | [4.5 d](/filings/0001104659-26-029004.md) | [4.3](/filings/0001558370-25-006384.md) | [4.3](/filings/0001558370-25-010180.md) | [4.5](/filings/0001104659-25-105924.md) | [7.6 d](/filings/0001104659-26-029004.md) | [16.2](/filings/0001104659-26-055322.md) | [20.4](/filings/0001104659-26-094078.md) | [20.2](/filings/0001104659-25-105924.md) | [20.1 d](/filings/0001104659-26-029004.md) | [18.3](/filings/0001104659-26-055322.md) | [20.3](/filings/0001104659-26-094078.md) |
| Gross profit | $m | [11.8](/filings/0001558370-24-015160.md) | [15.8 d](/filings/0001104659-26-029004.md) | [13.1](/filings/0001558370-25-006384.md) | [12.2](/filings/0001558370-25-010180.md) | [14.0](/filings/0001104659-25-105924.md) | [14.9 d](/filings/0001104659-26-029004.md) | [15.7](/filings/0001104659-26-055322.md) | [17.8](/filings/0001104659-26-094078.md) | [17.1](/filings/0001104659-25-105924.md) | [21.7 d](/filings/0001104659-26-029004.md) | [16.2](/filings/0001104659-26-055322.md) | [21.2](/filings/0001104659-26-094078.md) |
| Research and development | $m | [2.2](/filings/0001558370-24-015160.md) | [2.2 d](/filings/0001104659-26-029004.md) | [2.3](/filings/0001558370-25-006384.md) | [2.2](/filings/0001558370-25-010180.md) | [2.4](/filings/0001104659-25-105924.md) | [5.8 d](/filings/0001104659-26-029004.md) | [1.6](/filings/0001104659-26-055322.md) | [1.8](/filings/0001104659-26-094078.md) | [1.5](/filings/0001104659-25-105924.md) | [1.7 d](/filings/0001104659-26-029004.md) | [1.4](/filings/0001104659-26-055322.md) | [1.3](/filings/0001104659-26-094078.md) |
| Operating income | $m | [(8.9)](/filings/0001558370-24-015160.md) | [(4.4) d](/filings/0001104659-26-029004.md) | [(6.9)](/filings/0001558370-25-006384.md) | [(8.5)](/filings/0001558370-25-010180.md) | [(7.7)](/filings/0001104659-25-105924.md) | [(11.5) d](/filings/0001104659-26-029004.md) | [(11.0)](/filings/0001104659-26-055322.md) | [(8.1)](/filings/0001104659-26-094078.md) | [(7.3)](/filings/0001104659-25-105924.md) | [(5.0) d](/filings/0001104659-26-029004.md) | [(9.0)](/filings/0001104659-26-055322.md) | [(1.5)](/filings/0001104659-26-094078.md) |
| Interest expense | $m | [1.2](/filings/0001558370-24-015160.md) | [1.8 d](/filings/0001558370-25-003833.md) | [1.8](/filings/0001558370-25-006384.md) | [2.0](/filings/0001558370-25-010180.md) | [1.7](/filings/0001104659-25-105924.md) | [1.8 d](/filings/0001558370-25-003833.md) | [1.9](/filings/0001104659-26-055322.md) | [2.0](/filings/0001104659-26-094078.md) | [2.2](/filings/0001104659-25-105924.md) | [2.3 d](/filings/0001104659-26-029004.md) | [2.3](/filings/0001104659-26-055322.md) | [2.1](/filings/0001104659-26-094078.md) |
| Net income | $m | [(9.4)](/filings/0001558370-24-015160.md) | [(5.4) d](/filings/0001104659-26-029004.md) | [(7.9)](/filings/0001558370-25-006384.md) | [(9.8)](/filings/0001558370-25-010180.md) | [(13.3)](/filings/0001104659-25-105924.md) | [(12.7) d](/filings/0001104659-26-029004.md) | [(12.7)](/filings/0001104659-26-055322.md) | [(10.1)](/filings/0001104659-26-094078.md) | [(9.0)](/filings/0001104659-25-105924.md) | [(7.2) d](/filings/0001104659-26-029004.md) | [(10.8)](/filings/0001104659-26-055322.md) | [(3.4)](/filings/0001104659-26-094078.md) |
| Diluted EPS | $ per share | [(0.33)](/filings/0001558370-24-015160.md) | not reported | [(0.27)](/filings/0001558370-25-006384.md) | [(0.33)](/filings/0001558370-25-010180.md) | [(0.44)](/filings/0001104659-25-105924.md) | not reported | [(0.21)](/filings/0001104659-26-055322.md) | [(0.15)](/filings/0001104659-26-094078.md) | [(0.13)](/filings/0001104659-25-105924.md) | not reported | [(0.16)](/filings/0001104659-26-055322.md) | [(0.05)](/filings/0001104659-26-094078.md) |
| Basic EPS | $ per share | [(0.33)](/filings/0001558370-24-015160.md) | not reported | [(0.27)](/filings/0001558370-25-006384.md) | [(0.33)](/filings/0001558370-25-010180.md) | [(0.44)](/filings/0001104659-25-105924.md) | not reported | [(0.21)](/filings/0001104659-26-055322.md) | [(0.15)](/filings/0001104659-26-094078.md) | [(0.13)](/filings/0001104659-25-105924.md) | not reported | [(0.16)](/filings/0001104659-26-055322.md) | [(0.05)](/filings/0001104659-26-094078.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [35.8](/filings/0001558370-23-018015.md) | [59.7](/filings/0001104659-26-029004.md) | [47.7](/filings/0001558370-25-006384.md) | [42.6](/filings/0001558370-25-010180.md) | [20.9](/filings/0001104659-25-105924.md) | [18.5](/filings/0001104659-26-029004.md) | [20.2](/filings/0001104659-26-055322.md) | [11.0](/filings/0001104659-26-094078.md) | [28.0](/filings/0001104659-25-105924.md) | [28.1](/filings/0001104659-26-094078.md) | [13.2](/filings/0001104659-26-055322.md) | [19.2](/filings/0001104659-26-094078.md) |
| Current assets | $m | [71.0](/filings/0001558370-23-018015.md) | [93.8](/filings/0001558370-25-003833.md) | [81.9](/filings/0001558370-24-007073.md) | [75.5](/filings/0001558370-24-011800.md) | [53.5](/filings/0001558370-24-015160.md) | [58.1](/filings/0001104659-26-029004.md) | [60.7](/filings/0001558370-25-006384.md) | [56.1](/filings/0001558370-25-010180.md) | [64.9](/filings/0001104659-25-105924.md) | [61.6](/filings/0001104659-26-094078.md) | [47.2](/filings/0001104659-26-055322.md) | [53.2](/filings/0001104659-26-094078.md) |
| Total assets | $m | [93.0](/filings/0001558370-23-018015.md) | [116](/filings/0001558370-25-003833.md) | [104](/filings/0001558370-24-007073.md) | [96.8](/filings/0001558370-24-011800.md) | [74.1](/filings/0001558370-24-015160.md) | [141](/filings/0001104659-26-029004.md) | [142](/filings/0001558370-25-006384.md) | [135](/filings/0001558370-25-010180.md) | [145](/filings/0001104659-25-105924.md) | [142](/filings/0001104659-26-094078.md) | [125](/filings/0001104659-26-055322.md) | [132](/filings/0001104659-26-094078.md) |
| Current liabilities | $m | [15.3](/filings/0001558370-23-018015.md) | [19.8](/filings/0001558370-25-003833.md) | [14.5](/filings/0001558370-24-007073.md) | [29.3](/filings/0001558370-24-011800.md) | [16.9](/filings/0001558370-24-015160.md) | [31.3](/filings/0001104659-26-029004.md) | [24.8](/filings/0001558370-25-006384.md) | [27.8](/filings/0001558370-25-010180.md) | [28.9](/filings/0001104659-25-105924.md) | [30.5](/filings/0001104659-26-094078.md) | [28.3](/filings/0001104659-26-055322.md) | [28.3](/filings/0001104659-26-094078.md) |
| Total liabilities | $m | [55.0](/filings/0001558370-23-018015.md) | [81.6](/filings/0001558370-25-003833.md) | [76.2](/filings/0001558370-24-007073.md) | [77.4](/filings/0001558370-24-011800.md) | [64.7](/filings/0001558370-24-015160.md) | [109](/filings/0001104659-26-029004.md) | [102](/filings/0001558370-25-006384.md) | [103](/filings/0001558370-25-010180.md) | [114](/filings/0001104659-25-105924.md) | [115](/filings/0001104659-26-094078.md) | [108](/filings/0001104659-26-055322.md) | [110](/filings/0001104659-26-094078.md) |
| Long-term debt | $m | [36.9](/filings/0001558370-23-018015.md) | [59.3](/filings/0001558370-25-003833.md) | [59.4](/filings/0001558370-24-007073.md) | [46.1](/filings/0001558370-24-011800.md) | [46.0](/filings/0001558370-24-015160.md) | [55.2](/filings/0001104659-26-029004.md) | [55.3](/filings/0001558370-25-006384.md) | [55.5](/filings/0001558370-25-010180.md) | [65.7](/filings/0001104659-25-105924.md) | [65.8](/filings/0001104659-26-094078.md) | [61.3](/filings/0001104659-26-055322.md) | [61.5](/filings/0001104659-26-094078.md) |
| Current portion of debt | $m | not reported | not reported | not reported | [13.6](/filings/0001558370-24-011800.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [37.9](/filings/0001558370-24-015160.md) | [34.2](/filings/0001558370-25-003833.md) | [27.7](/filings/0001558370-24-015160.md) | [19.4](/filings/0001558370-24-015160.md) | [9.4](/filings/0001558370-24-015160.md) | [27.7](/filings/0001104659-26-029004.md) | [35.5](/filings/0001558370-25-006384.md) | [27.1](/filings/0001558370-25-010180.md) | [27.4](/filings/0001104659-25-105924.md) | [22.4](/filings/0001104659-26-094078.md) | [13.3](/filings/0001104659-26-055322.md) | [17.9](/filings/0001104659-26-094078.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.1) d](/filings/0001558370-24-015160.md) | [2.1 d](/filings/0001104659-26-029004.md) | [(12.0)](/filings/0001558370-25-006384.md) | [(5.0) d](/filings/0001558370-25-010180.md) | [(5.4) d](/filings/0001104659-25-105924.md) | [(8.6) d](/filings/0001104659-26-029004.md) | [(17.0)](/filings/0001104659-26-055322.md) | [(3.5) d](/filings/0001104659-26-094078.md) | [(0.8) d](/filings/0001104659-25-105924.md) | [0.9 d](/filings/0001104659-26-094078.md) | [(9.4)](/filings/0001104659-26-055322.md) | [(1.0) d](/filings/0001104659-26-094078.md) |
| Capital expenditure | $m | [0.6 d](/filings/0001558370-24-015160.md) | [0.9 d](/filings/0001104659-26-029004.md) | [0.4](/filings/0001558370-25-006384.md) | [0.6 d](/filings/0001558370-25-010180.md) | [0.4 d](/filings/0001104659-25-105924.md) | [0.1 d](/filings/0001104659-26-029004.md) | [0.2](/filings/0001104659-26-055322.md) | [0.3 d](/filings/0001104659-26-094078.md) | [0.1 d](/filings/0001104659-25-105924.md) | [0.2 d](/filings/0001104659-26-029004.md) | [0.2](/filings/0001104659-26-055322.md) | [0.4 d](/filings/0001104659-26-094078.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [27.0](/filings/0001558370-23-018015.md) | [28.0](/filings/0001558370-24-007073.md) | [28.6](/filings/0001558370-24-011800.md) | [28.9](/filings/0001558370-24-015160.md) | [29.5](/filings/0001558370-25-006384.md) | [30.1](/filings/0001558370-25-010180.md) | [30.3](/filings/0001104659-25-105924.md) | [61.5](/filings/0001104659-26-055322.md) | [66.2](/filings/0001104659-26-094078.md) | [67.3](/filings/0001104659-25-105924.md) | [69.6](/filings/0001104659-26-055322.md) | [73.1](/filings/0001104659-26-094078.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 76,197,222 at 2026-08-05, from the cover of the [10-Q filed 2026-08-11](/filings/0001104659-26-094078.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.